Protalix BioTherapeutics Inc (PLX)
1.14
-0.02
(-1.72%)
USD |
NYAM |
May 03, 16:00
1.145
0.00 (0.00%)
After-Hours: 20:00
Protalix BioTherapeutics Revenue (TTM): 65.49M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 65.49M |
| September 30, 2023 | 63.62M |
| June 30, 2023 | 67.46M |
| March 31, 2023 | 41.14M |
| December 31, 2022 | 47.64M |
| September 30, 2022 | 47.57M |
| June 30, 2022 | 45.44M |
| March 31, 2022 | 43.12M |
| December 31, 2021 | 38.35M |
| September 30, 2021 | 49.30M |
| June 30, 2021 | 48.03M |
| March 31, 2021 | 52.57M |
| December 31, 2020 | 62.90M |
| September 30, 2020 | 61.16M |
| June 30, 2020 | 64.62M |
| March 31, 2020 | 65.90M |
| December 31, 2019 | 54.69M |
| September 30, 2019 | 47.29M |
| June 30, 2019 | 45.37M |
| March 31, 2019 | 37.96M |
| December 31, 2018 | 34.24M |
| September 30, 2018 | 28.19M |
| June 30, 2018 | 23.38M |
| March 31, 2018 | 24.90M |
| December 31, 2017 | 21.08M |
| Date | Value |
|---|---|
| September 30, 2017 | 18.85M |
| June 30, 2017 | 16.00M |
| March 31, 2017 | 11.41M |
| December 31, 2016 | 9.199M |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | -5.889M |
| June 30, 2015 | -3.518M |
| March 31, 2015 | -2.168M |
| December 31, 2014 | 3.523M |
| September 30, 2014 | 3.385M |
| June 30, 2014 | 3.037M |
| March 31, 2014 | 3.415M |
| December 31, 2013 | 0.00 |
| September 30, 2013 | 10.44M |
| June 30, 2013 | 12.47M |
| March 31, 2013 | 34.66M |
| December 31, 2012 | 34.42M |
| September 30, 2012 | 35.06M |
| June 30, 2012 | 30.57M |
| March 31, 2012 | 6.078M |
| December 31, 2011 | 8.35M |
| September 30, 2011 | 13.44M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
38.35M
Minimum
Dec 2021
67.46M
Maximum
Jun 2023
53.25M
Average
49.30M
Median
Sep 2021
Revenue (TTM) Benchmarks
| Agenus Inc | 156.31M |
| InfuSystems Holdings Inc | 125.78M |
| AIM ImmunoTech Inc | 0.202M |
| Perspective Therapeutics Inc | 0.00 |
| Armata Pharmaceuticals Inc | -- |